Gerd Jomrich , Maximilian Gruber , Elisabeth S. Gruber , Jakob Mühlbacher , Sanja Radosavljevic , Lavinia Wilfing , Daniel Winkler , Gerald Prager , Christian Reiterer , Barbara Kabon , Helmuth Haslacher , Klaus Sahora , Martin Schindl
{"title":"胰腺导管腺癌患者平均血球容积的预后意义及多模式治疗","authors":"Gerd Jomrich , Maximilian Gruber , Elisabeth S. Gruber , Jakob Mühlbacher , Sanja Radosavljevic , Lavinia Wilfing , Daniel Winkler , Gerald Prager , Christian Reiterer , Barbara Kabon , Helmuth Haslacher , Klaus Sahora , Martin Schindl","doi":"10.1016/j.jviscsurg.2023.06.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim of the study</h3><p>Mean corpuscular volume (MCV) has shown mounting evidence as a prognostic indicator in a number of malignancies. The aim of this study was to examine the prognostic potential of pretherapeutic MCV among patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront resection or resection after neoadjuvant treatment (NT).</p></div><div><h3>Patients and methods</h3><p>Consecutive patients with PDAC who underwent pancreatic resection between 1997 and 2019 were included in this study. Neoadjuvantly treated patients’ serum MCV was measured before NT and before surgery. In patients undergoing upfront resection serum MCV was measured before surgery. Median MCV values were used as cut-off to distinguish high from low MCV values.</p></div><div><h3>Results</h3><p>Five hundred and forty-nine (438 upfront resected and 111 neoadjuvantly treated) patients were included in this study. Multivariate analysis revealed, that high MCV before and after NT, were independent negative prognostic factors for overall survival (<em>P</em> <!--><<!--> <!-->0.01, respectively). Furthermore, the median MCV value from before to after NT increased significantly (<em>P</em> <!--><<!--> <!-->0.001, Wilcoxon signed-rank test) and was (<em>P</em> <!-->=<!--> <!-->0.03, Wilcoxon rank sum test) associated with tumor response to NT.</p></div><div><h3>Conclusion</h3><p>High MCV is an independent adverse prognostic factor in patients with resectable neoadjuvantly treated PDAC and may qualify as useful indicator to help physicians to provide personalized prognostication.</p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1878788623001157/pdfft?md5=136b81cbab7dea632490fb3df598e3a2&pid=1-s2.0-S1878788623001157-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Prognostic significance of mean corpuscular volume in patients with pancreatic ductal adenocarcinoma and multimodal treatment\",\"authors\":\"Gerd Jomrich , Maximilian Gruber , Elisabeth S. Gruber , Jakob Mühlbacher , Sanja Radosavljevic , Lavinia Wilfing , Daniel Winkler , Gerald Prager , Christian Reiterer , Barbara Kabon , Helmuth Haslacher , Klaus Sahora , Martin Schindl\",\"doi\":\"10.1016/j.jviscsurg.2023.06.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aim of the study</h3><p>Mean corpuscular volume (MCV) has shown mounting evidence as a prognostic indicator in a number of malignancies. The aim of this study was to examine the prognostic potential of pretherapeutic MCV among patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront resection or resection after neoadjuvant treatment (NT).</p></div><div><h3>Patients and methods</h3><p>Consecutive patients with PDAC who underwent pancreatic resection between 1997 and 2019 were included in this study. Neoadjuvantly treated patients’ serum MCV was measured before NT and before surgery. In patients undergoing upfront resection serum MCV was measured before surgery. Median MCV values were used as cut-off to distinguish high from low MCV values.</p></div><div><h3>Results</h3><p>Five hundred and forty-nine (438 upfront resected and 111 neoadjuvantly treated) patients were included in this study. Multivariate analysis revealed, that high MCV before and after NT, were independent negative prognostic factors for overall survival (<em>P</em> <!--><<!--> <!-->0.01, respectively). Furthermore, the median MCV value from before to after NT increased significantly (<em>P</em> <!--><<!--> <!-->0.001, Wilcoxon signed-rank test) and was (<em>P</em> <!-->=<!--> <!-->0.03, Wilcoxon rank sum test) associated with tumor response to NT.</p></div><div><h3>Conclusion</h3><p>High MCV is an independent adverse prognostic factor in patients with resectable neoadjuvantly treated PDAC and may qualify as useful indicator to help physicians to provide personalized prognostication.</p></div>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1878788623001157/pdfft?md5=136b81cbab7dea632490fb3df598e3a2&pid=1-s2.0-S1878788623001157-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1878788623001157\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878788623001157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
Prognostic significance of mean corpuscular volume in patients with pancreatic ductal adenocarcinoma and multimodal treatment
Aim of the study
Mean corpuscular volume (MCV) has shown mounting evidence as a prognostic indicator in a number of malignancies. The aim of this study was to examine the prognostic potential of pretherapeutic MCV among patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront resection or resection after neoadjuvant treatment (NT).
Patients and methods
Consecutive patients with PDAC who underwent pancreatic resection between 1997 and 2019 were included in this study. Neoadjuvantly treated patients’ serum MCV was measured before NT and before surgery. In patients undergoing upfront resection serum MCV was measured before surgery. Median MCV values were used as cut-off to distinguish high from low MCV values.
Results
Five hundred and forty-nine (438 upfront resected and 111 neoadjuvantly treated) patients were included in this study. Multivariate analysis revealed, that high MCV before and after NT, were independent negative prognostic factors for overall survival (P < 0.01, respectively). Furthermore, the median MCV value from before to after NT increased significantly (P < 0.001, Wilcoxon signed-rank test) and was (P = 0.03, Wilcoxon rank sum test) associated with tumor response to NT.
Conclusion
High MCV is an independent adverse prognostic factor in patients with resectable neoadjuvantly treated PDAC and may qualify as useful indicator to help physicians to provide personalized prognostication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
